Recurrence included ctDNA recurrence, radiographic recurrence, or concurrent ctDNA and imaging recurrence. Over a median duration of 26 months, 45 patients (24.5%) had ctDNA- or imaging-confirmed ...

Circulating tumor DNA (ctDNA) has been found to have limited clinical benefits when added to standard recommended surveillance among patients with stages 2 to 4 colorectal cancer who underwent ...

During her presentation, Shah commented on the study’s findings regarding the role of ctDNA testing in guiding adjuvant treatment decisions. “When asked whether postoperative ctDNA results ...

Consistent with previous studies, ctDNA status predicted 3-year DFS, which was 86.5% in patients with ctDNA-negative tests and 33.7% among patients with positive results (P <0.0001).

The median time to NLCB was 21.2 months for patients with undetectable ctDNA, 8.5 months for patients with detectable ctDNA in the control arm (survival time ratio [STR], 0.40; 90% CrI, 0.31-0.51 ...

Patients with hormone receptor (HR)-positive early breast cancer who underwent ultra-sensitive tissue-free circulating tumor DNA (ctDNA) demonstrated detections of ctDNA, according to findings from a ...

In the combination group, median recurrence-free survival (RFS) was 16.59 months in patients who had ctDNA positivity at baseline versus 68.11 months in those who were ctDNA negative (HR 2.98, 95% ...

Comparatively, for those who were ctDNA-positive, disease-free survival rates were just 45.9% and 35.5%, respectively, regardless of whether those patients received adjunctive chemotherapy. At the ...

Utilizing next-generation sequencing (NGS), the plasma ctDNA results demonstrated high concordance with tissue biopsy at baseline across tumor types and mutations.

Lalan Wilfong, MD, of Thyme Care and Texas Oncology, discusses a session on circulating tumor DNA (ctDNA) and shares insight as chair of the Community Oncology Alliance (COA) Payer Reform Committee.